


REMARKS

The substitute pages include modifications made to the international application under Article 34. The claims have been further amended to eliminate the multiple dependencies and to add claims 31-71. An Abstract of the Disclosure has also been added.

Entry of the amendments and early consideration and allowance are respectfully requested.

Respectfully submitted,


James E. Nilles

Registration No. 16,663

Date: December 11, 2001

NILLES & NILLES, S.C.
777 East Wisconsin Avenue, Suite 2000
Milwaukee, WI 53202
Telephone (414) 276-0977
Facsimile (414) 276-0982

ds G:\Data\CLIENT\28\018\PrelAmend.doc

10048489 034800

Version With Markings to Show Changes Made

CLAIMS

We claim:

3. A composition as defined in claim 1 [or 2], wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
4. A composition as defined in [any one of claims 1-3] claim 1, wherein said fish protein is cod fish protein.
12. A use as defined in [any one of claims 6-11] claim 6, wherein said fish protein is cod fish protein.
19. A method as defined in claim 13, [14, 16 or 17,] wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.
20. A method as defined in [any one of claims 13-19] claim 13, wherein said fish protein is cod fish.
24. A composition as defined in claim 22 [or 23], wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
25. A composition as defined in [any one of claims 22-24] claim 22, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
29. A method as defined in claim 26, [27 or 28,] wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.